한빛사논문
- 조회330
Gyeongseon Shin1, Beom Kyung Kim2, SeungJin Bae1, Hankil Lee3,4, Sang Hoon Ahn2
1College of Pharmacy, Ewha Womans University, Seoul, the Republic of Korea
2Department of Internal Medicine, Yonsei University College of Medicine, Seoul, the Republic of Korea
3College of Pharmacy, Ajou University, Suwon, Gyeonggi-do, the Republic of Korea
4Department of Biohealth Regulatory Science, Ajou University, Suwon, Gyeonggi-do, the Republic of Korea
Correspondence : Hankil Lee, Sang Hoon Ahn
*Gyeongseon Shin and Beom Kyung Kim contributed equally to this work.
Abstract
Background/aims: The World Health Organization (WHO) aims to eliminate hepatitis C Virus (HCV) by 2030, therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new approach. We aimed to evaluate disease burden reduction using the HCVST screening strategy and identify the most cost-effective approach.
Methods: We developed a dynamic open-cohort Markov model to assess the long-term effects and cost-effectiveness of HCVST in the Republic of Korea from 2024 to 2030. Strategies for comparison included universal, birth cohort, high-risk group screening, and no screening, focusing on the following: (1) incremental cost-effectiveness ratio (ICER) per disability-adjusted life-year (DALY) saved; (2) severe liver disease cases; and (3) liver-related death reduction.
Results: Universal HCVST screening is the most effective strategy for achieving the WHO goal by 2030, substantially lowering the incidence of severe liver disease by 71% and preventing liver-related deaths by 69 %, thereby averting 267,942 DALYs. Moreover, with an ICER of $8,078 per DALY and high cost-effectiveness, the sensitivity results prove that cost-effectiveness is robust. Although high-risk group screening offers the lowest cost compared with other strategies, its effectiveness in preventing severe liver disease is minimal, falling short of the current WHO goal.
Conclusions: Our study confirms that universal HCVST screening is a cost-effective strategy aligned with the WHO goal to eliminate HCV by 2030. Despite its higher costs compared to risk-based screening, the disease burden can be significantly reduced by providing effective HCVST access to individuals who might otherwise not be tested.
논문정보
- Research article
- 2024년 10월 (BRIC 등록일 2024-10-07)
- 국내 연구진
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기
